Ichiro Nakashima

Professor

Tohoku Medical and Pharmaceutical University

Japan

Research Interests

Explore related searches

Professors in Japan

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Ichiro Nakashima is a faculty member at Tohoku Medical and Pharmaceutical University in Japan. His research focuses on multiple sclerosis, neuromyelitis optica spectrum disorder, and related autoimmune conditions, as indicated by his recent articles. He has contributed significantly to understanding the clinical implications of these diseases in the Japanese population, particularly during the COVID-19 pandemic.

Articles (26)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (9)

Nasrin Asgari

Professor

University of Southern Denmark

DENMARK

View details

Zsolt Illes

Professor

DENMARK

View details

Kengo Nagashima

Lecturer (part-time)

Nippon Medical School

JAPAN

View details

Noriko Isobe

Professor and Chairperson

Kyushu University

JAPAN

View details

Maria José Sá

Universidade da Beira Interior Faculdade de Ciências da Saúde

PORTUGAL

View details

norio chihara

Project Associate Professor

Kobe University Hospital

JAPAN

View details

Friedemann Paul

GERMANY

View details

Masayuki Tahara

Chief

National University Hospital

JAPAN

View details

Shuhei Nishiyama

Assistant Professor

Tohoku University Hospital

JAPAN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Ichiro Nakashima

Research Interests

Explore related searches

Contact this professor

About

Articles (26)

Pulmonary Nodular Lymphoid Hyperplasia in a Case of Overlapping Neuromyelitis Optica Spectrum Disorder and Myasthenia Gravis

Effect of Disease‐Modifying Treatments in Japanese Patients With Multiple Sclerosis During the Coronavirus Disease 2019 Pandemic

Clinical value of the Japanese version of patient‐reported multiple sclerosis neuropsychological screening questionnaire

Safety and Effectiveness of Satralizumab in Japanese Patients with Neuromyelitis Optica Spectrum Disorder: A 6-month Interim Analysis of Post-marketing Surveillance

Different Complement Activation Patterns Following C5 Cleavage in MOGAD and AQP4-IgG+NMOSD.

Characterization of Japanese multiple sclerosis patients with progression independent of relapse activity: A 2-year multicenter cohort study.

Continuous diffuse brain atrophy independent of relapse as a hallmark of multiple sclerosis beginning from relapsing-remitting stage

Real-world management of patients with neuromyelitis optica spectrum disorder using satralizumab: Results from a Japanese claims database

Stochastic models for the onset and disease course of multiple sclerosis.

Brain volume loss in Japanese patients with multiple sclerosis is present in the early to middle stage of the disease

Immediate and sustained terminal complement inhibition with ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder.

Basal Ganglia Atrophy and Impaired Cognitive Processing Speed in Multiple Sclerosis.

Enlarged choroid plexus in multiple sclerosis is associated with increased lesion load and atrophy in white matter but not gray matter atrophy.

Clinical practice guidelines for multiple sclerosis, neuromyelitis optica spectrum disorder, and myelin oligodendrocyte glycoprotein antibody-associated disease 2023 in Japan

Employment status of multiple sclerosis patients in Japan

Prevalence of, and Disability Due to, Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder in Japan by the Fifth Nationwide Survey

Epidemiological and clinical characteristics of myelin oligodendrocyte glycoprotein antibody-associated disease in a nationwide survey

Ravulizumab in Aquaporin‐4–Positive Neuromyelitis Optica Spectrum Disorder

White blood cell count profiles in anti-aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorder and anti-myelin oligodendrocyte glycoprotein antibody-associated disease.

Diagnosis and classification of optic neuritis.

A Response to: Letter to the Editor Regarding "Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder".

Calculating and Comparing the Annualized Relapse Rate and Estimating the Confidence Interval in Relapsing Neurological Diseases.

Follow-up of retinal thickness and optic MRI after optic neuritis in anti-MOG antibody-associated disease and anti-AQP4 antibody-positive NMOSD.

Compassionate open-label use of rituximab following a randomised clinical trial against neuromyelitis optica (RIN-2 study): B cell monitoring-based administration.

Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension

A case of ischemic stroke accompanied by multiple arterial dissections associated with Klippel-Feil syndrome.

Collaborators (9)

Nasrin Asgari

Zsolt Illes

Kengo Nagashima

Noriko Isobe

Maria José Sá

norio chihara

Friedemann Paul

Masayuki Tahara

Shuhei Nishiyama

Make your next move.